US Stock Movement | Zai Lab (ZLAB.US) rises over 2% with positive Phase Ib data for investigational ADC Zoci

Zhihu Finance APP reports that on Friday, Zai Lab (ZLAB.US) shares surged nearly 10% in early trading and, as of press time, were up more than 2% at $22.62. According to reports, on October 23, Zai Lab announced the global Phase Ib clinical study data of its investigational antibody-drug conjugate (ADC) Zocilurtatug Pelitecan (short name “Zoci”, previously codenamed ZL-1310) for first-line extensive-stage small cell lung cancer. The related results will be presented on October 26 at the 2026 European Society for Medical Oncology (ESMO) Congress.